Searched for
DESIDUSTAT
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...- Zydus’ Desidustat gets USFDA orphan drug status for sickle cell diseaseZydus Lifesciences announced a significant development today. The US Food and Drugs Administration has granted Orphan Drug Designation to D...
- Zydus gets USFDA's orphan drug designation for beta-thalassemia productZydus Lifesciences announced a significant development for beta-thalassemia patients. The US Food and Drug Administration has granted Orpha...
- Zydus eyes M&A, licensing to build its US specialty businessZydus Lifesciences is exploring mergers, acquisitions, and licensing to bolster its specialty portfolio in the US, particularly for the pot...
- Stocks in news: RIL, HCL Tech, HDFC Life, PVR Inox, JSW InfraThe domestic brokerage on Monday reported a consolidated net profit at Rs 423 crore in Q2FY25, which was up 39% from Rs 304 crore reported ...
- Sun Pharma scouting for innovative therapies to boost India businessApproved by the Indian drug regulator in May 2023, sovateltide can be administered within 24 hours for the treatment of ischemic stroke, al...
- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...
- Zydus bets big on proprietary drugs to boost revenueSharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards develo...
- Sun Pharma to market Zydus' novel anti-CKD drug desidustat in India“The addition of RYTSTAT further strengthens our nephrology portfolio in India," said Kirti Ganorkar, CEO - India Business, Sun Pharma.
- Zydus gets DCGI nod for drug to treat anaemia associated with chronic kidney diseaseZydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a f...
- Cadila Healthcare Q3 Results: Firm posts 5% decline in profit at Rs 500 crConsolidated total revenue from operations stood at Rs 3,655 crore during the quarter under review as compared to Rs 3,633 crore in the yea...
- Zydus Cadila seeks DCGI approval for novel oral pill to treat anaemia in kidney patientsThe pill technically called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor can be given to both patients who are on dialysi...
- Zydus Cadila says 'positive results' from phase 2 studies of COVID-19 drug Desidustat in MexicoIn June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidate Des...
- Zydus Cadila gets nod from Mexican authority for clinical trials of COVID-19 therapyIn a regulatory filing, Zydus Cadila said it had received approval from the Mexican regulatory authority Cofepris to conduct clinical trial...
- Zydus Cadila gets approval from Mexican authority to test COVID-19 drugLast week, Zydus had received approval from Indian authorities to start human trials for its COVID-19 vaccine contender - the second Indian...
- Zydus & CMS enter pact for Desidustat in Greater ChinaThe agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) no...
Load More
